Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Get Free Report) shares were down 5.1% on Friday. The stock traded as low as $3.85 and last traded at $3.88. 96,872 shares traded hands during trading, a decline of 49% from the average session volume of 191,188 shares. The stock had previously closed at $4.09.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on NMAD shares. Wall Street Zen downgraded shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings raised shares of Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.
View Our Latest Stock Report on NMAD
Lixte Biotechnology Stock Down 5.1%
The business has a fifty day moving average price of $4.30 and a 200-day moving average price of $5.31. The company has a market cap of $62.47 million, a P/E ratio of -3.88 and a beta of 1.25.
Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter.
Institutional Investors Weigh In On Lixte Biotechnology
A number of institutional investors have recently made changes to their positions in the stock. Equitable Holdings Inc. bought a new position in shares of Lixte Biotechnology during the 2nd quarter worth approximately $74,000. FNY Investment Advisers LLC bought a new stake in Lixte Biotechnology in the second quarter valued at $330,000. BlackRock Inc. bought a new stake in Lixte Biotechnology in the second quarter valued at $564,000. Finally, Legacy Wealth Managment LLC ID bought a new position in shares of Lixte Biotechnology during the 2nd quarter worth about $4,457,000. Institutional investors own 5.10% of the company’s stock.
About Lixte Biotechnology
Lixte Biotechnology Holdings, Inc is a clinical-stage biotechnology company focused on developing cancer treatments based on protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to therapy. The company’s research is intended to identify ways to inhibit PP2A and improve the effectiveness of existing cancer treatments.
Lixte’s lead investigational program, LB-100, is a small-molecule PP2A inhibitor being evaluated in combination with other therapies for cancer.
Featured Stories
- Five stocks we like better than Lixte Biotechnology
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
